DR. YUSRA ASAD

DR. LALIT VERMA, DR. AVNINDRA GUPTA, DR. OBULI N. RAMACHANDRAN

Abstract

The emergence of Anti-VEGFs – bevacizumab, ranibizumab and aflibercept proved to be a revolution in the treatment of multiple retinal diseases such as age related macular degeneration, diabetic macular edema, cystoid macular edema, retinopathy of prematurity among others. As the biologic’s patent are expiring and with the advent of biosimilars from multiple pharmaceutical companies (Alcon, Intas, Cipla,..), we do a comparative analysis of the efficacy and economics of these biosimilars and their relevance in the current era. Also, with the emergence of better manufacturing and purification processes it is imperative that the biologics and biosimilars become better. Hence, we examine the role these biosimilars play in our current treatment regimes and try to extract the BEST amongst the betters.